Department of Microbiology & Immunology, Albert Einstein College of Medicine, Bronx, NY 10461, USA.
Infect Immun. 2010 Jan;78(1):441-52. doi: 10.1128/IAI.00506-09. Epub 2009 Nov 9.
Cryptococcus neoformans causes severe, and often fatal, disease (cryptococcosis) in immunocompromised patients, particularly in those with HIV/AIDS. Although resistance to cryptococcosis requires intact T-cell immunity, a possible role for antibody/B cells in protection against natural disease has not been definitively established. Previous studies of the antibody response to the C. neoformans capsular polysaccharide glucuronoxylomannan (GXM) have demonstrated that patients who are at increased risk for cryptococcosis have lower serum levels of GXM-reactive IgM than those who are not at risk, leading to the hypothesis that IgM might contribute to resistance to cryptococcosis. To determine the influence of IgM on susceptibility to systemic cryptococcosis in a murine model, we compared the survival of mice deficient in serum IgM (secretory IgM deficient [sIgM(-/-)]) and C57BL/6 x 129Sv (control) mice after intraperitoneal infection with C. neoformans strain 24067 and analyzed the splenic B- and T-cell subsets by flow cytometry and the serum and splenic cytokine/chemokine and serum antibody profiles of each mouse strain. The results showed that sIgM(-/-) mice survived significantly longer than control mice when challenged with 10(5) CFU of C. neoformans 24067. Naïve sIgM(-/-) mice had higher levels of B-1 (CD5(+)) B cells, proinflammatory mediators (interleukin-6 [IL-6], IL-1beta, MIP-1beta, tumor necrosis factor alpha [TNF-alpha], and gamma interferon [IFN-gamma]), and anti-inflammatory mediators (IL-10 and IL-13) and significantly higher titers of GXM-specific IgG2a 3 weeks postinfection. In addition, CD5(+) splenocytes from both mouse strains had fungicidal activity against C. neoformans. Taken together, these results suggest that the inflammatory milieu in sIgM(-/-) mice might confer enhanced resistance to systemic cryptococcosis, stemming in part from the antifungal activity of B-1 B cells.
新型隐球菌引起严重的、通常是致命的疾病(隐球菌病),特别是在免疫功能低下的患者中,尤其是那些患有 HIV/AIDS 的患者。尽管抗隐球菌病需要完整的 T 细胞免疫,但抗体/B 细胞在预防自然疾病方面的可能作用尚未得到明确证实。先前对新型隐球菌荚膜多糖葡聚糖(GXM)抗体反应的研究表明,患有隐球菌病风险增加的患者的血清 GXM 反应性 IgM 水平低于无风险患者,导致假设 IgM 可能有助于抵抗隐球菌病。为了确定 IgM 在小鼠模型中对系统性隐球菌病易感性的影响,我们比较了缺乏血清 IgM(分泌型 IgM 缺乏[ sIgM(-/-) ])和 C57BL/6 x 129Sv(对照)小鼠在腹腔内感染新型隐球菌 24067 后的存活率,并通过流式细胞术分析了脾 B 和 T 细胞亚群以及每只小鼠的血清和脾细胞因子/趋化因子和血清抗体谱。结果表明,当用 10(5)CFU 新型隐球菌 24067 挑战时, sIgM(-/-) 小鼠的存活率明显高于对照小鼠。幼稚的 sIgM(-/-) 小鼠具有更高水平的 B-1(CD5(+))B 细胞、促炎介质(白细胞介素-6[IL-6]、白细胞介素-1β、MIP-1β、肿瘤坏死因子-α[TNF-α]和γ干扰素[IFN-γ])和抗炎介质(白细胞介素-10 和白细胞介素-13),以及感染后 3 周 GXM 特异性 IgG2a 的滴度明显更高。此外,来自两种小鼠品系的 CD5(+) 脾细胞对新型隐球菌具有杀菌活性。综上所述,这些结果表明, sIgM(-/-) 小鼠的炎症环境可能赋予其对系统性隐球菌病的增强抵抗力,部分原因是 B-1 B 细胞的抗真菌活性。